Transneural Therapeutics Welcomes Mark A. Demitrack, MD
Transneural Therapeutics, a biotechnology company at the forefront of developing treatments for neuropsychiatric disorders, is proud to announce the appointment of Dr. Mark A. Demitrack, MD, as its new Chief Research and Development Officer. With more than 30 years of experience in the industry, Dr. Demitrack brings a wealth of knowledge and expertise in the development of drugs targeting the central nervous system (CNS).
A Leader in CNS Drug Development
Charmaine Lykins, the Chief Executive Officer of Transneural Therapeutics, expressed enthusiasm about Dr. Demitrack's addition to the team. "Mark is a highly accomplished leader with unparalleled scientific and clinical development expertise specific to neuropsychiatry. I'm excited to welcome Mark to the team. He has a comprehensive command of all phases of drug development and a track record that includes multiple drug approvals. Mark's leadership will be invaluable to our efforts to progress our pipeline assets, including the development of TN-001 for depression and PTSD," she stated.
Dr. Demitrack's Extensive Experience
Dr. Demitrack, an internationally recognized neuropsychiatrist, has an impressive background that includes previous roles as Chief Medical Officer at Trevena and Neuronetics. At Neuronetics, he led the development and successful launch of the NeuroStar TMS Therapy System, targeting treatment-resistant major depression. Additionally, he has valuable experience from his tenure at Lilly, where he was pivotal in the development of the antidepressant duloxetine (Cymbalta).
Exciting Prospects for TN-001
In his new role, Dr. Demitrack is excited about the potential of TN-001, the company's lead candidate, which aims to provide meaningful relief for individuals suffering from Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). He expressed, "It's an exciting time to join Transneural as we advance our lead candidate, TN-001, a novel therapeutic that could provide meaningful relief to people living with MDD and PTSD. I look forward to building our research and development organization and partnering with an experienced team of neuroscience leaders focused on bringing new and potentially better treatment options to people living with these debilitating conditions."
Impressive Academic Contributions
Dr. Demitrack's academic credentials are equally impressive. He served as a faculty member of the Department of Psychiatry at the University of Michigan Medical School, where he conducted influential clinical research on the neuroendocrine pathophysiology of mood disorders. He has authored more than 100 articles, book chapters, and reviews and is a Fellow of the American Psychiatric Association, as well as a Member of the American College of Neuropsychopharmacology.
The Vision of Transneural Therapeutics
Transneural Therapeutics is dedicated to transforming the treatment landscape for neuropsychiatric diseases through innovative neuroplastogens. Their lead asset, TN-001, is a dual 5-HT2A partial agonist and 5-HT2B antagonist. This unique drug aims to engage serotonergic receptors to deliver rapid and enduring antidepressant efficacy comparable to psychedelic treatments, yet without the associated hallucinations or dissociative effects.
Media Contact Information
For media inquiries, please reach out to Liz Cogan. She can be contacted at +1.619.780.7684 for further details about Transneural’s advancements and initiatives.
Frequently Asked Questions
Who is Dr. Mark A. Demitrack?
Dr. Mark A. Demitrack is a neuropsychiatrist with over 30 years of experience in CNS drug development, recently appointed as Chief Research and Development Officer at Transneural Therapeutics.
What is the role of TN-001?
TN-001 is meant to provide relief for individuals suffering from Major Depressive Disorder and PTSD, offering innovative therapeutic properties via serotonergic engagement.
What expertise does Dr. Demitrack bring to Transneural?
Dr. Demitrack brings extensive experience in clinical research, drug development, and strategic planning, having worked with prominent organizations in the biotechnology sector.
How does Transneural Therapeutics aim to transform treatments?
Transneural Therapeutics focuses on pioneering neuroplastogens to change the treatment approaches for neuropsychiatric disorders, seeking to deliver new, effective therapies.
What recognition has Dr. Demitrack achieved in his field?
He is a Fellow of the American Psychiatric Association and a member of the American College of Neuropsychopharmacology, showcasing his contributions to the field of psychiatry.
